Trial Profile
A Single Masked, Randomized Comparison of the Safety and Efficacy of 0.2 and 0.5 µg/Day Fluocinolone Acetonide/Medidur in Patients With Exudative Age Related Macular Degeneration Who Have Received Lucentis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Apr 2018
Price :
$35
*
At a glance
- Drugs Fluocinolone acetonide (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- Acronyms MAP
- 28 Mar 2018 According to an EyePoint Pharmaceuticals media release, pSivida Corp. changed its name to EyePoint Pharmaceuticals.
- 16 Sep 2014 New trial record